a half dose recombinant hepatitis b vaccine ( hbvax ii , msd , 5 micrograms ) was investigated for efficacy in the prevention of perinatal hepatitis b virus ( hbv ) transmission in high risk neonates born from e-antigen positive hbsag carrier mothers as compared to the half-standard dose regimen of plasma derived hepatitis b vaccine ( hbvax , msd , 10 micrograms ) .
C0019163
hepatitis b
C0062527
hepatitis b vaccine